Walgreens Spent $14 Billion Becoming a Doctor. It Ended Up Going Private.

Walgreens already had the real estate. Roughly nine thousand corners in America, each within a few minutes of where most people live, each with a pharmacy counter and a parking lot. The logic was almost irresistible: if you already own the place people walk into when they feel sick, why not put a doctor in the back? So Walgreens didn't just rent space to a clinic chain. It bought one - then bought more of it, then bought a second chain on top of it. Within four years that decision had erased more than $14 billion of segment operating value in a single fiscal year⁶ and helped march a hundred-year-old public company into the arms of a private-equity buyer.⁵

The official story is that Walgreens was building the future of integrated, affordable care - the drugstore reborn as a front door to the health system. The truer story is plainer and more expensive: Walgreens bought scale in a business whose unit economics it had not yet proven, and discovered the cost of the proof only after it had already paid for the scale.

It bought the clinics before it knew the clinics worked

Start with the money, because the money is the whole tell. Walgreens put $1 billion into VillageMD in 2020, then a further $5.2 billion in October 2021 to take its stake to about 63%.¹⁰ That second check is the one that matters. A $1 billion stake is a thoughtful option on a new business - a way to learn whether placing a primary-care doctor next to a pharmacy actually changes how people spend, refill, and get well. The $5.2 billion that followed wasn't an option. It was a commitment to a national rollout, made before the early clinics had shown they could cover their own cost of care, retain patients, and turn the cross-sell into margin. The order was backwards: scale first, proof later.

Then it doubled the wager. In November 2022, VillageMD - the company Walgreens now controlled - agreed to acquire Summit Health-CityMD for $8.9 billion, with Walgreens contributing $3.5 billion in a 50/50 mix of equity and debt and emerging with roughly 53% ownership.³ Note the structure carefully, because it is where the risk hid. Walgreens was not the legal acquirer; VillageMD was. But Walgreens was funding the acquirer, guaranteeing its growth story, and consolidating its losses. It had built a machine that let it pour capital into an unproven model while the deal headlines said someone else was buying.

The adjacency that looked free was the most expensive part

Here is the thesis, plainly: Walgreens didn't fail because clinics-next-to-pharmacies was a bad idea. It failed because it treated proximity as proof. Owning the corner makes it cheap to put a doctor there; it does nothing to guarantee the doctor's practice earns a return. Primary care is a low-margin, capital-hungry business with long payback periods, and running clinics profitably is a different competence from running a retail pharmacy. Walgreens bought its way into that competence at national scale and then had to learn it in public, on a balance sheet that was already thin.

When the learning arrived, it arrived as a write-off. In Q2 FY2024 Walgreens recorded a $12.4 billion non-cash impairment against VillageMD goodwill - an accounting admission that the asset was worth a fraction of what it had paid.¹ That single charge drove the U.S. Healthcare segment to a $14.2 billion operating loss for FY2024, against $1.7 billion the year before, and helped push the company to an $8.6 billion net loss - nearly triple the prior year.⁶ An impairment is not a cash event; you don't write a check for it. But it is the market's verdict made official: the value you promised was never going to materialize.

The clinic map tells the same story from the ground. By early 2024 VillageMD had moved from closing 60 locations to closing 160, and had already exited 140 across Florida, Indiana, Chicago, Boston, Rhode Island, and Las Vegas.⁷ You don't retreat from six states in a year if the model is working. You retreat because the math at each location refused to cooperate - and because you opened too many of them, too fast, to find out.

That last point is worth sitting with. Cigna, a sophisticated health insurer that knows the care business cold, put $2.5 billion into VillageMD in late 2022 and wrote down $1.8 billion of it within roughly eighteen months.⁸ When the smartest co-investor in the room marks its own stake down by 72%, the problem was never Walgreens' execution alone. The problem was the asset.

But wasn't the strategy directionally right?

The fair objection is that Walgreens read the future correctly. Healthcare is migrating out of hospitals and toward convenient, lower-cost settings; the drugstore is a natural front door; integrating pharmacy, primary care, and specialty referral is exactly the play that several serious companies are pursuing. By this reading, Walgreens was early and unlucky, not wrong - undone by post-pandemic cost inflation and a brutal capital market, not by strategy. There is truth in this. The vision was not foolish.

But the steelman concedes the real mistake, because it concedes that the idea was right and the sequencing was fatal. A directionally correct bet sized wrong is still a wrong bet. The disciplined version of this strategy was available and visible: keep the $1 billion option, expand clinic by clinic, prove the cohort economics in a few markets, and only then deploy billions to scale what worked. Walgreens did the opposite. It committed $5.2 billion, then $3.5 billion more, on a thesis it was still testing - and the test came back negative after the capital was already spent. The market's response was not subtle. By March 2025 the company that had been a Dow component for decades agreed to be taken private at $11.45 a share, an equity value near $10 billion, with as much as $23.7 billion in total value only if assumed debt and a contingent VillageMD payout were included.⁴ On August 28, 2025, the deal closed and Walgreens left the public markets after nearly a century.⁵

Walgreens erased more than $14 billion in U.S. Healthcare segment operating value in a single year to learn a lesson its own footprint had disguised: that the corner you already own makes the doctor cheap to install but does nothing to make the practice pay.⁶ It out-located its judgment. It mistook the ease of starting for evidence of working, and confused the low cost of the first clinic with the unproven economics of the thousandth. The adjacency wasn't the cause of every problem at Walgreens - but it was the accelerant, the bet that turned a struggling retailer into a distressed one. The drugstore on the corner is still there. The public company that owned it is not.